Nemaura Medical to Present at the Maxim Group 2022 Virtual Growth Conference
March 24 2022 - 4:24PM
Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company
focused on developing and commercializing wearable diagnostic
devices and supporting personalized lifestyle coaching programs,
announces today that CEO Dr. Faz Chowdhury will participate at the
Maxim Group 2022 Virtual Growth Conference, which is being held on
March 28-30, 2022.
Dr. Chowdhury will present a corporate overview
which will become available on Monday, March 28, 2022 at 9:00 a.m.
ET.
Investors can view the presentation by
registering for the conference here and also
request a one-on-one meeting with management to be arranged
following the conclusion of the conference.
About Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical technology
company developing and commercializing wearable diagnostic devices.
The company is currently commercializing sugarBEAT® and
proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device,
is a non-invasive and flexible continuous glucose monitor (CGM)
providing actionable insights derived from real time glucose
measurements and daily glucose trend data, which may help people
with diabetes and pre-diabetes to better manage, reverse, and
prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S.
FDA. proBEAT™ combines non-invasive glucose data processed
using artificial intelligence and a digital healthcare subscription
service and has been launched in the U.S. as a general wellness
product as part of its BEAT®diabetes program that is currently
undergoing pilot studies.
Additionally, Nemaura has launched Miboko, a new
metabolic health and well-being program using a non-invasive
glucose sensor along with an AI mobile application that helps a
user understand how certain foods and lifestyle habits can impact
one’s overall metabolic health and well-being. Nemaura believes
that up to half the population could benefit from a sensor and
program that monitors metabolic health and well-being.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Contact:
Jules AbrahamCORE IR917-885-7378julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Apr 2023 to Apr 2024